GenSpera, Inc. (GenSpera) is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin with a prodrug delivery system that targets the release of the drug within the tumor. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. G-115 and G-114 are activated by the enzyme prostate specific antigen (PSA). G-301 is activated by the enzyme human glandular kallikrein 2 (hK2).